LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Big Changes Start Small

23/05/2022
BLOG

by Dr Claire Skentelbery, Director General, EuropaBio, and
José Peres, NAC & SME Coordinator, EuropaBio


Humans are, by nature, curious beings. Scientists and children more so. Both share this remarkable quality of asking too many questions in too little time. Most often, inconveniently.

This curiosity to break things apart and see what is inside is one of the main drivers for innovation. Innovations, very rarely, are radical, disruptive breakthroughs. They usually are a series of minor and simple improvements in an existing product, method or process. They are incremental changes to fix or understand an issue. They are the result of curious minds.

Small and medium-sized enterprises and entrepreneurs are the primary deliverers of innovation. They are often mentioned for their role in job creation, economic growth and social cohesion. Still, one outstanding feature that often goes unmentioned is the significance of their role in creating new and better health solutions and save lives.

Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They can be used to cure, diagnose or prevent diseases, and focus on diverse conditions, including genetic disorders, cancers or long-term disease, increasingly in a single treatment, eliminating the need for unpleasant and long term interventions that reduce QoL and an active economic and societal role for the patient. ATMPs offer unique long-term benefits for patients and society. One of the main drivers for their discovery and manufacturing are SMEs.

Among the most common challenges for SMEs working in the ATMP field is the lack of investment, and how competitiveness can be unlocked. When we analyse the issue in further detail, we can easily conclude that it is not merely about financing itself but the investment environment as a whole. Public and private resources can be much more efficiently managed if Europe addresses entrepreneurship's main challenges to growth. SMEs face giant regulatory hurdles, a fragmented market and countless other challenges, including access to skills for each scientific and business stage. When discussing long decision-times, we often regard them as an inconvenience, however for most SMEs, it means they will not be able to reach the market at all, not just later.

Despite these challenges, small enterprises and entrepreneurs continue to push forward, as is their unstoppable nature.

In 2017, the story of Hassan, a Syrian "butterfly child" treated in Germany with the gene therapy developed by Prof. Michele De Luca, co-founder of the university spin-off Holostem was widely and deservedly reported. The approval for compassionate use from the German regulatory authorities, saved the little patient allowing him a quality of life he never had before.

As for SME ingenuity, to address the lack of qualified personnel, notably on ATMP GMPs, Theracell, a Greek SME, sponsored a Master's degree in partnership with the University of Patras & University of West Attika that offers hands-on experience and prepares the next generation of European ATMP professionals.

Theracell and Holostem are just a few examples of how European SMEs are realising a true knowledge-based economy while delivering life-saving long-term solutions to patients.

EuropaBio is the home of European Biotechnology SMEs, and EuropaBio's SME Platform is commonplace for them to share experiences, challenges, practices and ambitions. On May 31st, we will hear them and discuss their main challenges in regulatory pathways, market fragmentation and other bottlenecks for growth and how we raise their voices and together, move forward.

Share
Alexandra Simionca
Alexandra Simionca

Related posts

21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
19/03/2025

Measuring the Economic Footprint of the Biotechnology Industry in the European Union


Read more
19/03/2025

Biotech as a critical economic asset for Europe: WifOR Institute study updated for EuropaBio


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.